CLYM (Climb Bio) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $12.90
! 3 Warning Signs
View Full Analysis

What is Climb Bio Other Stockholders Equity?

Climb Bio CLYM -2.93% 22 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Climb Bio's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

Climb Bio's quarterly Other Stockholders Equity declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.00 Mil).

Climb Bio's annual Other Stockholders Equity stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil).

Climb Bio Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Climb Bio's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio Other Stockholders Equity Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -0.00

Climb Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 -0.00 0.00
CLYM
22GF Score
Climb Bio Inc CLYM
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Climb Bio (CLYM) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Climb Bio and its competitors.
Is Climb Bio's Other Stockholders Equity too high?
Climb Bio's current Other Stockholders Equity is $0.00 Mil. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Other Stockholders Equity compare to XOMA and CTMX?
Climb Bio's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Climb Bio and its competitors. Climb Bio's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Climb Bio (CLYM), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.90
Price